Clinical implications of the global multidrug-resistant tuberculosis epidemic

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 15, Issue , 2015, Pages s37-s42

  Kumar, Kartik ^a,b   Abubakar, Ibrahim ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WHITTINGTON HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Diagnostics; Epidemiology; Multidrug resistant tuberculosis; Treatment

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; BEDAQUILINE; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; ARTHRALGIA; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; DIARRHEA; DNA HYBRIDIZATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG REPOSITIONING; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EPIDEMIC; EXTRAPULMONARY TUBERCULOSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINE PROBE ASSAY; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEXT GENERATION SEQUENCING; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NUTRITIONAL SUPPORT; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; UNITED KINGDOM; VOMITING; EPIDEMICS; GREAT BRITAIN; HEALTH; MICROBIOLOGY; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EPIDEMICS; GLOBAL HEALTH; GREAT BRITAIN; HUMANS; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84988530434     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.15-6-s37     Document Type: Review

References (39)

1. World Health Organisation. The end TB strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO, 2015. Available online at www.who.int/tb/post2015-TBstrategy.pdf?ua=1 [Accessed 11 June 2015].
2. World Health Organisation. Definitions and reporting framework for tuberculosis - 2013 revision (updated December 2014. Geneva: WHO, 2014. Available online at http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345-eng.pdf[Accessed 11 June 2015].
3. World Health Organisation. Drug-resistant TB surveillance & response. Supplement global tuberculosis report 2014. Geneva: WHO, 2014. Available online at http://apps.who.int/iris/bitstream/10665/137095/1/WHO-HQ-TB-2014.12-eng.pdf?ua=1 [Accessed 11 June 2015].
4. World Health Organisation. Global tuberculosis report 2014. Geneva: WHO, 2014. Available online at http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf?ua=1 [Accessed 11 June 2015].
5. Public Health England. Tuberculosis in the UK: 2014 report. London: Public Health England, 2014. Available online at www.gov.uk/government/uploads/system/uploads/attachment-data/file/360335/TB-Annual-report-4-0-300914.pdf [Accessed 11 June 2015].
6. World Health Organisation. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO, 2014. Available online at http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809-eng.pdf?ua=1&ua=1 [Accessed 11 June 2015].
7. Francis RS, Curwen MP. Major surgery for pulmonary tuberculosis: final report. Tubercle 1964;45(Suppl):5-79.
8. Sinclair D, Abba K, Grobler L, Sudarsanam TD. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev 2011;(11):CD006086.
9. Keal JL, Capstick T, Ricketts WMR, Whitehead N, Kon OM. P97 Multi-drug resistant tuberculosis: The first UK guideline for treatment monitoring. Thorax 2013;68:A119.
10. Potter JL, Capstick Ricketts WMR T et al. A UK based resource to support the monitoring and safe use of anti-tuberculosis drugs and second line treatment of multidrugresistant tuberculosis. TB Drug Monographs, 2015. Available online www.tbdrugmonographs.co.uk [Accessed 11 June 2015].
11. Whalen C, Horsburgh CR, Hom D et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995 Jan;151:129-35.
12. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO, 2011. Available online at http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf [Accessed 11 June 2015].
13. HIV Drug Interactions (online website). Available online at www.hiv-druginteractions.org [Accessed 11 June 2015].
14. Weyer K, Mirzayev F, Migliori GB et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42:252-71.
15. Drobniewski F, Cooke M, Jordan J et al. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess 2015;19:1-188.
16. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: WHO, 2011. Available online at http://whqlibdoc.who.int/publications/2011/9789241501545-eng.pdf [Accessed 11 June 2015].
17. Lange C, Abubakar I, Alffenaar JW et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014;44:23-63.
18. Sohn H, Aero AD, Menzies D et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 2014;58:970-6.
19. Somoskovi A, Deggim V, Ciardo D, Bloemberg GV. Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance. J Clin Microbiol 2013;51:3127-9.
20. World Health Organisation. Policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva: WHO, 2008. Available online at www.who.int/tb/features-archive/policy-statement.pdf?ua=1 [Accessed 11 June 2015].
21. De Beenhouwer H, Lhiang Z, Jannes G et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis 1995;76:425-30.
22. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005;5:62.
23. Traore H, Fissette K, Bastian I et al. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis 2000;4:481-4.
24. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet 2008;24:133-41.
25. Walker TM, Kohl TA, Omar SV et al. Modernizing Medical Microbiology (MMM) Informatics Group. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015;15:1193-202.
26. Takiff HE, Feo O. Clinical value of whole-genome sequencing of Mycobacterium tuberculosis. Lancet Infect Dis 2015;15:1077-90.
27. World Health Organisation. Frequently asked questions on bedaquiline. Geneva: WHO, 2015. Available online at www.who.int/tb/challenges/mdr/bedaquilinefaqs/en/ [Accessed 11 June 2015].
28. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7.
29. Diacon AH, Pym A, Grobusch M P et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-32.
30. US Food and Drug Administration. FDA news release. Silver Spring, MD ; FDA, 31 December 2012. Available online at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm [Accessed 11 June 2015].
31. World Health Organisation. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva: WHO, 2013. Available online at http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482-eng.pdf [Accessed 11 June 2015].
32. Kwon YS, Jeong BH, Koh WJ. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Expert Opin Pharmacother 2015;16:253-61.
33. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60
34. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosispatients. Int J Tuberc Lung Dis 2011;15:949-54.
35. European Medicines Agency. European Medicines Agency recommends two new treatment options for tuberculosis. London: European Medicines Agency, 2013. Available online at www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/11/news-detail-001972.jsp&mid=WC0b01ac058004d5c1 [Accessed 11 June 2015].
36. RESIST-TB. DR-TB clinical trial progress report. Available online at www.resisttb.org/?page-id=1602 [Accessed 11 June 2015].
37. Falzon D, Gandhi N, Migliori GB et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68.
38. Jacobson KR, Tierney DB, Jeon CY et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
39. Abubakar I, Zignol M, Falzon D et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013;13:529-39.